ArticleThe New England journal of medicine2017
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05136287 (SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Semaglutide versus glp-1 receptor agonists. effectiveness , safety and quality of life in patients with diabetes mellitus 2. observational, prospective and multicenter study. several study.
Who cites it
58 citing papers in PubMed.
- Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.Diabetes, obesity & metabolism · 2026Trial
- Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.Obesity (Silver Spring, Md.) · 2025Trial
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.Cardiovascular diabetology · 2021Trial
- Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.Scientific reports · 2021Trial
- Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.Biomedical reports · 2026Article
- Redox-Driven Blood-Nerve Barrier Dysfunction in Diabetic Peripheral Neuropathy: Mechanisms and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2026Review
- [Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation.Frontiers in physiology · 2026Review
- Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Disproportionality analysis of GLP-1 receptor agonists combined with metformin based on the FAERS database.Scientific reports · 2025Article
- Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.BMC ophthalmology · 2025Article
- A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors.Journal of clinical and translational hepatology · 2024Article
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this mapReview
- Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema.Journal of diabetes and its complications · 2024Article
- Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation.Clinical transplantation · 2024Article
- Strategies for chronic coronary disease: A brief guide for clinicians.NPJ cardiovascular health · 2024Review
- Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.Frontiers in endocrinology · 2024Article
- Understanding Diabetic Cardiomyopathy: Insulin Resistance and Beyond.Heart international · 2024Review
- Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.Heart international · 2024Article
- Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge.Current atherosclerosis reports · 2023Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28249135What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.